Raras
Buscar doenças, sintomas, genes...
Coriorretinopatia serosa central
ORPHA:443079CID-10 · H35.7CID-11 · 9B75.2DOENÇA RARA

A retinopatia serosa central (RSC), também conhecida como coriorretinopatia serosa central, é um líquido acumulado no espaço sub-retiniano. Ela é uma doença ocular que causa deficiência visual, geralmente temporária, geralmente em um olho. A doença é considerada de causa desconhecida. Afeta principalmente homens brancos na faixa etária de 20 a 50 e ocasionalmente outros grupos. Acredita-se que a condição seja exacerbada pelo estresse ou pelo uso de corticosteróide.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Acúmulo de fluido sub-retiniano na mácula, causando descolamento do epitélio pigmentar. Manifesta-se com visão turva, distorção visual e escotoma central, mais comum em homens jovens.

Pesquisas ativas
10 ensaios
87 total registrados no ClinicalTrials.gov
Publicações científicas
3.355 artigos
Último publicado: 2026 Mar
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: H35.7
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico3.355PubMed
Últimos 10 anos200publicações
Pico2025115 papers
Linha do tempo
2026Hoje · 2026🧪 2000Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

🧬

Nenhum gene associado encontrado

Os dados genéticos desta condição ainda estão sendo catalogados.

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
3Fase 33
2Fase 21
1Fase 12
·Pré-clínico14
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 20 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Coriorretinopatia serosa central

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

6 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

87 ensaios clínicos encontrados, 10 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

📖Melhor nível de evidência: Revisão
Timeline de publicações
2.291 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 2.291

#1

Combined Therapy Versus Fortified Anti-VEGF Monotherapy in Type C Polypoidal Choroidal Vasculopathy: Long-Term Outcomes and Exploratory Biomarker Insights.

International journal of molecular sciences2026 Jan 26

While standard anti- vascular endothelial growth factor (VEGF) therapy, with or without photodynamic therapy (PDT), is effective for patients with polypoidal choroidal vasculopathy (PCV), not all achieve optimal visual outcomes. This study aimed to compare fortified (double the dose and the volume of the standard one) anti-VEGF combined with PDT versus fortified anti-VEGF monotherapy and to investigate biomolecular profiles and disease relationships among PCV, neovascular age-related macular degeneration (nvAMD), and central serous chorioretinopathy (CSCR). The goal was to identify novel pathways to inform future therapeutic strategies, including hypoxia-inducible factors (HIF)-1α inhibitors. This retrospective cohort study included 23 eyes with indocyanine green-confirmed type C PCV. One eye treated with transpupillary thermotherapy was not included in the following two groups. Patients received either combined therapy (PDT + fortified-dose anti-VEGF; n = 12) or fortified-dose anti-VEGF monotherapy (n = 10). Primary outcomes were changes in best-corrected visual acuity (BCVA) and central retinal thickness (CRT). Secondary outcomes included injection burden and recurrence. Exploratory analyses examined aqueous biomarkers, including VEGF, placental growth factor (PlGF), β-catenin, HIF-1α, and Wnt1 across PCV, CSCR, and nvAMD to identify novel therapeutic targets. Significant (p = 0.003/p = 0.005) median CRT reduction was similar (p = 0.468) between groups (combined/monotherapy: 137.5 µm/106.5 µm). BCVA (median [Q1, Q3]) change in logarithm of the minimum angle of resolution (LogMAR) was not statistically significant (p = 0.279), with 0.25 [0.00, 0.98] in the combined group versus 0.00 [-0.03, 0.28] in the monotherapy group. Treatment burden of anti-VEGFs per person per year was lower with combined therapy (1.16 ± 0.47# PDT + 2.81 ± 0.92# anti-VEGF injections) compared with monotherapy (4.61 ± 1.49# injections). Six eyes demonstrated recurrence at a mean of 15.5 months. Incomplete regression of polyps and branching vascular networks was observed in all eyes. Exploratory biomarker analysis revealed significantly (p < 0.05) higher VEGF and PlGF levels in nvAMD compared with PCV. nvAMD also demonstrated significantly (p < 0.05) higher β-catenin and lower HIF-1α levels relative to PCV and CSCR, while no significant biomarker differences were observed between PCV and CSCR. Combined therapy or monotherapy with fortified anti-VEGFs reduced treatment burden and achieved significant anatomical improvement but did not yield superior functional outcomes, highlighting the therapeutic difficulty of type C PCV. Biomarker profiling revealed shared hypoxia-related mechanisms between PCV and CSCR, with elevated HIF-1α compared to nvAMD indicating a "preliminary" possible role for HIF-1α inhibitors. Differential expression of these biomarkers highlights additional molecular pathways that may inform future targeted interventions.

#2

Correction: Effect of photodynamic therapy on choroid of the medial area from optic disc in patients with central serous chorioretinopathy.

PloS one2026

[This corrects the article DOI: 10.1371/journal.pone.0282057.].

#3

The CFH-CFHR5 Locus in Wet Age-Related Macular Degeneration, Polypoidal Choroidal Vasculopathy, and Central Serous Chorioretinopathy.

Ophthalmology science2026 Feb

To evaluate the effects of haplotype-tagging single nucleotide polymorphisms (SNPs) in the complement factor H-complement factor H related 5 (CFH-CFHR5) locus on neovascular age-related macular degeneration (nAMD), polypoidal choroidal vasculopathy (PCV), and chronic central serous chorioretinopathy (cCSCR) in Chinese patients. Case-control genetic association study. A total of 846 patients (341 nAMD, 288 PCV, and 217 cCSCR including 43 with secondary macular neovascularization [MNV]) and 632 healthy Chinese controls. A total of 17 candidate SNPs were initially selected from the CFH-CFHR5 region; after excluding 5 SNPs that deviated from Hardy-Weinberg equilibrium, 12 SNPs were retained for the final analysis. Association analyses included logistic regression adjusted for age and sex and haplotype-based analysis using Haploview. Study-wide significance threshold was set at P < 0.0042 for allelic tests (Bonferroni-corrected for 12 SNPs) and at P < 0.05 for haplotype tests (adjusted using 10 000 permutations). Associations between individual SNPs and haplotypes in the CFH-CFHR5 locus with nAMD, PCV, and cCSCR (with or without MNV), respectively. The tagging SNP, rs12144939, for the CFHR3/1 deletion was significantly associated with nAMD (odds ratio [OR] = 0.37, P = 0.0031). Notably, we identified 3 candidate variants showing novel associations with PCV, including rs12144939 (OR = 0.29, P = 6.29 × 10-4), rs423641 in CFHR1 (OR = 0.74, P = 0.0038), and rs10922152 in CFHR5 (OR = 1.55, P = 0.0031). No SNP in this locus was associated with cCSCR without MNV, whereas CFH rs529825 was nominally associated with cCSCR with MNV (OR = 0.47, P = 0.0047). Similar patterns of haplotype associations were observed across the 3 maculopathies. Notably, the haplotype A-T-C-G spanning CFHR4, CFHR2, and CFHR5 (OR = 1.81, permutation P = 0.0099) and haplotype G-A-G within CFHR5 (OR = 1.56, permutation P = 0.025) were specifically associated with PCV. This study validates the association of the CFHR3/1 deletion (tagged by rs12144939) with nAMD. Furthermore, we reveal a novel genetic architecture for PCV within the CFH-CFHR5 locus, characterized by associations at rs12144939, rs423641 (CFHR1), and rs10922152 (CFHR5), as well as risk haplotypes unique to PCV. These findings underscore the critical role of CFH-related genes in PCV and provide new insights into its genetic mechanisms. The author has no/the authors have no proprietary or commercial interest in any materials discussed in this article.

#4

Selective Retina Therapy With Fundus Image-Based Titration in Central Serous Chorioretinopathy: Prospective Outcomes and Predictive Factors.

Translational vision science &amp; technology2026 Jan 05

We evaluated the clinical outcomes of selective retina therapy (SRT) with fundus image-based titration approach for central serous chorioretinopathy (CSC). Sixty eyes (60 participants) with chronic CSC prospectively underwent SRT. Treatment (527-nm wavelength, 1.7-µs pulse duration) targeted leakage sites identified via fundus fluorescein angiography. Pulse energy and micropulse number were adjusted based on test-spot fundus images. Changes in best-corrected visual acuity (BCVA), central foveal thickness, subfoveal choroidal thickness, and subretinal fluid (SRF) height were evaluated at baseline and at 1, 2, and 3 months post treatment. Retinal sensitivity was measured by microperimetry at baseline and 3 months. Outcomes were compared between eyes with completely resolved or residual SRF at 3 months. At 3 months, complete SRF resolution was observed in 80.8% of eyes (42/52). The mean SRF height decreased from 135.6 ± 81.9 µm to 28.0 ± 72.0 µm, and the mean central foveal thickness from 318.9 ± 88.0 µm to 231.9 ± 69.8 µm (both P < 0.001). In parallel, functional parameters also improved, with mean best-corrected visual acuity increasing from 0.17 ± 0.15 logarithm of the minimum angle of resolution to 0.06 ± 0.12 logarithm of the minimum angle of resolution and mean deviation of retinal sensitivity from -0.89 ± 1.65 dB to 0.02 ± 1.29 dB (both P < 0.001). Female sex was significantly associated with persistent SRF in both univariate and multivariable analyses (odds ratio, 30.794; 95% confidence interval, 2.996-774.668; P = 0.011). SRT with fundus image-based titration yielded favorable functional and anatomical outcomes in CSC. Female sex was associated with persistent SRF, although this finding should be interpreted cautiously. Fundus image-based titration translates selective retinal pigment epithelium targeting in selective retina therapy into a reproducible clinical approach for central serous chorioretinopathy. This strategy facilitates individualized treatment while remaining compatible with routine clinical practice.

#5

Neurosymbolic AI Framework for Explainable Retinal Disease Classification From OCT Images.

Translational vision science &amp; technology2026 Jan 05

Accurate classification of retinal diseases such as dry age-related macular degeneration, wet AMD, epiretinal membrane, full-thickness macular hole (MH), lamellar MH, and central serous chorioretinopathy (CSC) is essential for effective treatment and clinical decision-making. Traditional deep learning models, however, often struggle with imbalanced datasets and lack interpretability, limiting their translational applicability in ophthalmology. We propose a neurosymbolic framework that integrates a convolutional neural network (CNN) with a symbolic reasoning layer based on expert-defined clinical rules. A total of 10,846 optical coherence tomography images were retrospectively collected and categorized into seven diagnostic classes: dry AMD, wet AMD, epiretinal membrane, full-thickness MH, lamellar MH, central serous chorioretinopathy, and healthy retinas. Our neurosymbolic model achieved macro-precision 0.83, recall 0.82, and F1 0.81, on internal dataset, having slightly better performance than the CNN (0.64/0.83/0.68). On the external dataset, it retained superior performance, macro-precision 0.85, recall 0.79, F1 0.78, versus the CNN (0.73/0.64/0.59). Our hybrid neurosymbolic framework introduces a unified paradigm that couples symbolic reasoning with a conventional CNN, improving diagnostic performance while delivering transparent, clinically interpretable decisions. It is particularly effective for rare and complex conditions that often challenge end-to-end deep learning models. By integrating symbolic clinical logic with visual pattern recognition, the neurosymbolic model fosters trust in artificial intelligence-assisted diagnostics and supports precise, explainable decision-making in retinal care.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC2.623 artigos no totalmostrando 196

2026

CLINICAL AND IMAGING PREDICTORS OF BILATERAL INVOLVEMENT IN CENTRAL SEROUS CHORIORETINOPATHY.

Retina (Philadelphia, Pa.)
2026

Anterior uveal morphometrics in complex central serous chorioretinopathy: insights from ultrasound biomicroscopy and anterior segment optical coherence tomography.

Clinical &amp; experimental optometry
2026

Prognostic value of foveal choroidal vascular hyperpermeability on indocyanine green angiography in central serous chorioretinopathy.

Eye (London, England)
2026

Assessment of artifact-removed choriocapillaris flow voids in eyes with pachychoroid spectrum disorders.

Japanese journal of ophthalmology
2026

Ultra-widefield indocyanine green angiography findings of vortex veins in central serous chorioretinopathy.

Japanese journal of ophthalmology
2026

Long-term follow-up of PLACE and SPECTRA trials: outcomes after successful and unsuccessful half-dose photodynamic therapy for chronic central serous chorioretinopathy.

American journal of ophthalmology
2026

Photodynamic therapy and anti-vascular endothelial growth factor for acute central serous chorioretinopathy: An updated systematic review and meta-analysis.

Survey of ophthalmology
2026

Association Between Pseudoexfoliation Glaucoma and Central Serous Chorioretinopathy.

American journal of ophthalmology
2026

Inner Collagenous Layer Detachment: A Novel Optical Coherence Tomography Sign in Avascular Serous Pigment Epithelial Detachment Secondary to Central Serous Chorioretinopathy.

Ophthalmic surgery, lasers &amp; imaging retina
2026

Hormonal factors in the pathophysiology of central serous chorioretinopathy - a systematic review and meta-analysis.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
2026

Evaluation of static and dynamic pupillometry parameters in patients with central serous chorioretinopathy.

European journal of ophthalmology
2026

Central Serous Chorioretinopathy is Associated with Increased Cardiovascular Risk: An Artificial Intelligence-Based Retinal Analysis.

Ophthalmic epidemiology
2026

Childhood central serous chorioretinopathy: An uncommon cause of neurosensory macular detachment.

Archivos de la Sociedad Espanola de Oftalmologia
2026

Central Serous Chorioretinopathy in Parallel With Onset and Relapses of Minimal Change Nephrotic Syndrome: A 28-Year Case Follow-Up.

Cureus
2026

A bibliometric and visualized analysis of choriocapillaris from 2013 to 2023.

International journal of ophthalmology
2026

An intelligent segmentation method for leakage points in central serous chorioretinopathy based on fluorescein angiography images.

International journal of ophthalmology
2026

Demography, Clinical Characteristics and Long-Term Outcomes of Central Serous Chorioretinopathy in Women. MICRoN Report Number Fourteen.

American journal of ophthalmology
2026

Clinical Characteristics and Outcomes in Central Serous Chorioretinopathy with Subretinal Hyper-Reflective Material: MICRoN report 6.

American journal of ophthalmology
2026

Update on subthreshold micropulse laser treatment for retinal diseases: A narrative review.

Survey of ophthalmology
2026

Chronic Central Serous Chorioretinopathy with and without Myopia: Clinical Features and Response to Half-Dose Photodynamic Therapy.

Photodiagnosis and photodynamic therapy
2026

Eplerenone for Central Serous Chorioretinopathy: Is There Still Room for This Treatment?

Biomedicines
2025

Corticosteroid-induced central serous chorioretinopathy in a pemphigus vulgaris patient.

Dermatology online journal
2026

Outer Retinal Erosion and Outer Retinal Pinching at the Origin of Subretinal Fluid in Central Serous Chorioretinopathy.

American journal of ophthalmology
2026

The Amsler Grid in Everyday Practice: A Review of Its Role and Limitations in Primary Care.

Clinical ophthalmology (Auckland, N.Z.)
2026

Choroidal imaging biomarkers as predictors of recurrent central serous chorioretinopathy: A multicenter retrospective study - MICRoN report number five.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
2026

Secondary Multiple Evanescent White Dot Syndrome Associated with Active Central Serous Chorioretinopathy.

Retinal cases &amp; brief reports
2026

Choriocapillaris flow deficits and choroidal vascular index in the fellow eye of patients with central serous chorioretinopathy.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
2026

Combined Therapy Versus Fortified Anti-VEGF Monotherapy in Type C Polypoidal Choroidal Vasculopathy: Long-Term Outcomes and Exploratory Biomarker Insights.

International journal of molecular sciences
2026

The Role of Nailfold Videocapillaroscopy (NVC) in Evaluating Ocular Diseases: Insights into Retinal, Choroidal, and Optic Nerve Pathologies.

Journal of clinical medicine
2026

Risk factors for the development of subretinal fluid in the fellow eyes of patients with chronic central serous chorioretinopathy.

Acta ophthalmologica
2026

Increased peripapillary choroidal blood flow velocity in peripapillary pachychoroid syndrome: Three case reports with referential observations in central serous chorioretinopathy.

American journal of ophthalmology case reports
2026

Central Serous Chorioretinopathy: Etiology, Diagnosis, and Treatment.

Deutsches Arzteblatt international
2026

Long-term follow-up of chronic central serous chorioretinopathy patients receiving oral eplerenone and half-dose photodynamic therapy in the SPECTRA trial: SPECTRA trial report No. 4.

Acta ophthalmologica
2026

Association between central serous chorioretinopathy and personality types: A systematic review and meta-analysis.

Acta ophthalmologica
2026

Efficacy of Photodynamic Therapy in Chronic Central Serous Chorioretinopathy: A Retrospective Analysis at Hanusch Hospital, Vienna.

Klinische Monatsblatter fur Augenheilkunde
2026

Prevalence and associations of central serous chorioretinopathy in a population aged 50+ years. The Beijing Eye Study.

Eye (London, England)
2026

Large-caliber choroidal arteriovenous shunt in macular neovascularization: A brief report of a novel morphological finding.

Photodiagnosis and photodynamic therapy
2026

Hyperreflective choroidal foci may predict pachychoroid macular atrophy development in central serous chorioretinopathy.

Eye (London, England)
2026

Dichotomous pathogenesis drives therapeutic choice: A case report and review of literature differentiating glucocorticoid-induced from disease activity-associated central serous chorioretinopathy in lupus nephritis.

Lupus
2026

Proteomic Signature in Men with Central Serous Chorioretinopathy.

Journal of proteome research
2026

Venous Overload Choroidopathy With Coexisting Chronic Central Serous Chorioretinopathy and Uveal Effusion Syndrome.

Journal of vitreoretinal diseases
2026

The CFH-CFHR5 Locus in Wet Age-Related Macular Degeneration, Polypoidal Choroidal Vasculopathy, and Central Serous Chorioretinopathy.

Ophthalmology science
2026

Peripapillary intervortex venous anastomoses in central serous chorioretinopathy.

International ophthalmology
2025

Beyond the vision: central serous chorioretinopathy, anxiety and depression-a systematic review.

Frontiers in medicine
2026

Dim Flicker: An Endogenous Visual Percept and Its Disease Associations.

Journal of clinical medicine
2026

Vitreoretinal disease detection using artificial intelligence: a systematic review and meta-analysis.

International ophthalmology
2026

Bilateral Central Serous Chorioretinopathy in a Patient With XYY Syndrome.

Ophthalmic surgery, lasers &amp; imaging retina
2026

Off-label intravitreal brolucizumab and bevacizumab for chronic central serous chorioretinopathy.

International journal of ophthalmology
2026

Elevated Anxiety Levels in Central Serous Chorioretinopathy: Evidence from a Prospective Case-Control Study.

Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde
2026

Selective Retina Therapy With Fundus Image-Based Titration in Central Serous Chorioretinopathy: Prospective Outcomes and Predictive Factors.

Translational vision science &amp; technology
2026

Neurosymbolic AI Framework for Explainable Retinal Disease Classification From OCT Images.

Translational vision science &amp; technology
2026

Exploring retinal and choroidal characteristics on multimodal imaging in resolved central serous chorioretinopathy.

Eye (London, England)
2025

Punctate Hyperfluorescent Spots on Indocyanine Green Angiography in Eyes with Central Serous Chorioretinopathy and Patient Demographics.

Journal of clinical medicine
2025

A Novel Panmacular Strategy for Subthreshold Micropulse Laser in CSC: Two-Year Functional and Morphological Outcomes.

Journal of clinical medicine
2026

Long-term outcomes of titration-guided focal selective retina therapy for chronic central serous chorioretinopathy: retrospective real-world data analysis.

BMC ophthalmology
2026

Optical density ratio as a prognostic biomarker for chronicity in Central Serous Chorioretinopathy.

Retina (Philadelphia, Pa.)
2025

The "scolex" sign" - A distinct hyperreflective foci on the wall of serous pigment epithelial detachments in central serous chorioretinopathy - MICRON Report Number Seven.

Retina (Philadelphia, Pa.)
2025

Evaluation of Changes in Optical Coherence Tomography (OCT) Biomarkers After Oral Eplerenone Therapy in Chronic Central Serous Chorioretinopathy and Their Correlation to Functional Visual Outcome.

Cureus
2026

Pilot Study of Choroidal Synphlebia.

Retina (Philadelphia, Pa.)
2025

Imaging characteristics of macular neovascularization in chronic central serous chorioretinopathy patients.

Retina (Philadelphia, Pa.)
2025

A deeper assessment of various choroidal and demographic biomarkers among symptomatic pachychoroid spectrum entities within a tertiary referral center.

Retina (Philadelphia, Pa.)
2025

A deep learning-based pachychoroid index based on choroidal image patterns of central serous chorioretinopathy using enhanced-depth-imaging optical coherence tomography.

Japanese journal of ophthalmology
2025

Bilateral Central Serous Chorioretinopathy Associated With Tuberculosis in a Female Patient.

Cureus
2026

REDUCTION OF SCLERAL THICKNESS WITH TOPICAL FLUOROMETHOLONE IN MANAGEMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY COMPLICATED BY POSTERIOR CYSTOID DEGENERATION.

Retinal cases &amp; brief reports
2025

Severe bilateral chorioretinopathy associated with ipilimumab in a patient with metastatic melanoma.

GMS ophthalmology cases
2025

EXOGENOUS TESTOSTERONE USE AND ACUTE CENTRAL SEROUS CHORIORETINOPATHY IN A TRANSGENDER PATIENT.

Retinal cases &amp; brief reports
2025

Oral Eplerenone for Exudative Retinal Detachment Secondary to Central Serous Chorioretinopathy: A Case Report.

Cureus
2026

A Randomized-Controlled Trial of the Efficacy, Safety and Tolerability of Intravitreal Brolucizumab in Patients With Chronic Central Serous Chorioretinopathy With Persistent Fluid in the Absence of Choroidal Neovascular Membrane-BRICS Trial Report II.

American journal of ophthalmology
2026

The spectrum of pachychoroid neovasculopathy.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
2026

Pachychoroid pigment epitheliopathy and macular venous outflow abnormalities: the effects of venous stasis.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
2025

Selective and nonselective mineralocorticoid receptor antagonists in central serous chorioretinopathy: systematic review and meta-analysis.

BMC ophthalmology
2025

Systemic Lupus Erythematosus: Ophthalmological Safety Considerations of Emerging and Conventional Therapeutic Agents.

International journal of molecular sciences
2025

Multimodal imaging predictors of recurrence after photodynamic therapy in chronic central serous chorioretinopathy.

International ophthalmology
2025

Full-Spectrum Pachychoroid Manifestation in One Eye: A Case Report.

Case reports in ophthalmology
2025

A coarse-to-fine registration method for multimodal retinal images.

Scientific reports
2025

Seasonal variation in the incidence of central serous chorioretinopathy: A systematic review and meta-analysis.

Acta ophthalmologica
2025

Choroidal neovascularization as a trigger for central serous chorioretinopathy.

International journal of retina and vitreous
2025

Systemic C-reactive protein levels and central serous chorioretinopathy: A systematic review with meta-analysis.

Acta ophthalmologica
2025

Short-Term Topical Minoxidil Use Associated with Acute Central Serous Chorioretinopathy: A Case Report.

Case reports in ophthalmology
2025

When Erectile Dysfunction Therapy Clouds the Vision: ST-BRVO after Sildenafil in a Healthy Male.

Case reports in ophthalmology
2026

Subretinal Fluid Duration and Clinical Outcomes in Central Serous Chorioretinopathy: An Analysis of Time-to-Photodynamic Therapy.

American journal of ophthalmology
2025

Exogenous Hormone Use as a Predictor of Central Serous Chorioretinopathy Recurrence: A Comparative Analysis of Observation Versus Low-Fluence Photodynamic Therapy.

Journal of vitreoretinal diseases
2025

Selective retina therapy for central serous chorioretinopathy with focal choroidal excavation: a retrospective case series of six eyes.

International journal of retina and vitreous
2026

Clinical Features and Outcomes of Bullous Central Serous Chorioretinopathy: A Multicentric Cohort Study.

Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde
2025

Hyperreflective Choroidal Foci: A Comprehensive Review.

Journal of ophthalmic &amp; vision research
2026

Three-dimensional choroidal vessels assessment in central serous chorioretinopathy.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
2026

Evaluation of Long-Term Ocular Findings in Liver Transplant Patients: Comparison of Pediatric and Adult Age Groups.

Transplantation proceedings
2025

Three-Dimensional Choroidal Contour Mapping in Central Serous Chorioretinopathy and Fellow Eyes.

Translational vision science &amp; technology
2025

Visual Disturbance During Pregnancy: A Case Report of Central Serous Chorioretinopathy.

Cureus
2025

The urinary 6-sulfatoxymelatonin level in patients with central serous chorioretinopathy and its correlation with choroidal vasculature.

International ophthalmology
2025

A comparative study of choroidal thickness and pigment epithelial detachment in acute and chronic central serous chorioretinopathy in Nepalese patients.

PloS one
2026

Novel Finding of Retinal Aneurysmal Alterations in Patients Undergoing Fingolimod Therapy for Multiple Sclerosis.

Neurology and therapy
2025

Half-time photodynamic therapy for serous pigment epithelium detachment: anatomical and functional outcomes.

Photodiagnosis and photodynamic therapy
2026

Efficacy and safety of intravitreal faricimab for choroidal neovascularization secondary to central serous chorioretinopathy - a multicentre study.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
2026

Photobiomodulation Therapy with Low-Level Light in Chronic Central Serous Chorioretinopathy: A Pilot Study.

Ophthalmology and therapy
2025

Advances in minimally traumatic retinal laser therapy.

Expert review of medical devices
2025

Pentraxin-3 and Lipocalin-2 are decreased in patients with uveal effusion syndrome.

International ophthalmology
2026

Association of Migraine With Increased Risk of Central Serous Chorioretinopathy: A Retrospective Cohort Study.

American journal of ophthalmology
2026

Volumetric choroidal biomarkers in central serous chorioretinopathy using swept-source optical coherence tomography: a deep learning approach.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
2026

Retinal fingerprint pattern in central serous chorioretinopathy.

Retina (Philadelphia, Pa.)
2026

DIAGNOSTIC PERFORMANCE OF MACHINE LEARNING TECHNOLOGY USING OPTICAL COHERENCE TOMOGRAPHIC IMAGE IN RETINAL DISEASES PRESENTED WITH SUBRETINAL FLUID.

Retina (Philadelphia, Pa.)
2026

Corneal Nerve Abnormalities in Chronic Central Serous Chorioretinopathy.

Ophthalmology science
2025

Embossing enhances visualization of retinal pigment epithelium alterations in fundus autofluorescence in central serous chorioretinopathy.

European journal of ophthalmology
2025

Efficacy and Safety of Intravitreal Brolucizumab in Chronic Central Serous Chorioretinopathy: A Retrospective Cohort Study [Response to Letter].

Clinical ophthalmology (Auckland, N.Z.)
2025

Efficacy and Safety of Intravitreal Brolucizumab in Chronic Central Serous Chorioretinopathy: A Retrospective Cohort Study [Letter].

Clinical ophthalmology (Auckland, N.Z.)
2025

Changes in choriocapillaris blood flow following half-fluence, full-dose photodynamic therapy (PDT) and half-fluence, half-dose PDT in patients with central serous chorioretinopathy: A quantitative analysis of early post-treatment alterations.

Photodiagnosis and photodynamic therapy
2025

International consensuses and guidelines on central serous chorioretinopathy (CSC) by the Asia Pacific Vitreo-retina Society (APVRS), the Academy of Asia-Pacific Professors of Ophthalmology (AAPPO) and the Academia Retina Internationalis (ARI).

Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)
2025

Non-Neoplastic Disorders Mimicking Posterior Segment Inflammation.

Ocular immunology and inflammation
2025

Evaluation of Leak Sites in Central Serous Chorioretinopathy and the Effects of PDT on RPE by Polarization-Sensitive OCT.

Translational vision science &amp; technology
2026

Predictors of persistent central serous chorioretinopathy: a multicenter retrospective study - MICRoN report number four.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
2026

Evaluation of choriocapillaris perfusion changes in chronic central serous chorioretinopathy following Half-Dose photodynamic therapy.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
2025

Bilateral Choroidal Metastases Mimicking Central Serous Chorioretinopathy: A Diagnostic Challenge.

Cureus
2025

Secondary Choroidal Osteoma in the Setting of Uveal Pathology: 4 Case Reports and Review.

Ocular oncology and pathology
2026

THE ROLE OF EN FACE IMAGING OF RETINAL PIGMENT EPITHELIUM ALTERATIONS IN RAPID CLASSIFICATION OF CENTRAL SEROUS CHORIORETINOPATHY USING WIDEFIELD SWEPT-SOURCE OPTICAL COHERENCE TOMOGRAPHY.

Retina (Philadelphia, Pa.)
2025

A comprehensive overview: deep learning approaches to central serous chorioretinopathy diagnosis.

BMC ophthalmology
2026

Exogenous Testosterone Use Increases the Risk of Central Serous Chorioretinopathy.

American journal of ophthalmology
2025

Comparative efficacy of two different subthreshold yellow laser treatments for chronic central serous chorioretinopathy.

Journal francais d'ophtalmologie
2025

Pachychoroid Neovasculopathy, Intravitreal Injection, and Implications for Aeromedical Decision Making.

Aerospace medicine and human performance
2025

Efficacy and Safety of Intravitreal Brolucizumab in Chronic Central Serous Chorioretinopathy: A Retrospective Cohort Study.

Clinical ophthalmology (Auckland, N.Z.)
2024

Cyclodialysis Cleft following Intravitreal Injection; Case Report.

Journal of current ophthalmology
2025

Choroidal Vascular Fingerprints From Indocyanine Green Angiography Unveil Chorioretinal Disease State.

Investigative ophthalmology &amp; visual science
2026

Association between Choroidal Vascular Hyperpermeability and Vortex Vein Anastomoses in Central Serous Chorioretinopathy.

Ophthalmology science
2025

Pregnancy as a risk factor for central serous chorioretinopathy: A systematic review and meta-analysis.

Acta ophthalmologica
2025

Diagnostic and Management Challenges in Atypical Central Serous Chorioretinopathy Mimicking Vogt-Koyanagi-Harada Disease: A Case Report.

Cureus
2025

Flat irregular pigment epithelium detachments in chronic central serous chorioretinopathy: a focus on choroidal changes.

Eye (London, England)
2025

Efficacy of Intravitreal Brolucizumab for Chronic Central Serous Chorioretinopathy: A Pilot Study.

Journal of personalized medicine
2025

Micropulse laser therapy at 532, 577, and 810 nm for chronic central serous chorioretinopathy: a systematic review and Meta-analysis.

International journal of ophthalmology
2025

An autopsy case of bullous retinal detachment and hypopyon in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia.

American journal of ophthalmology case reports
2025

National study on the management of central serous chorioretinopathy.

Archivos de la Sociedad Espanola de Oftalmologia
2026

Double layer sign in chorioretinal diseases: Clinical significance and implications from multimodal imaging.

Survey of ophthalmology
2025

Association of Central Serous Chorioretinopathy With Endogenous or Exogenous Corticosteroids: A Report of 2 Cases.

JCEM case reports
2025

Efficacy of Topical Non-Selective and COX-2 Selective NSAIDs in Accelerating Resolution of Acute Central Serous Chorioretinopathy: A Retrospective Analysis.

Clinical ophthalmology (Auckland, N.Z.)
2025

Efficacy of subliminal laser in chronic central serous chorioretinopathy: A 2.5-Year retrospective study.

Lasers in medical science
2025

Choroidal vascular hyperpermeability patterns in central serous chorioretinopathy correlate with microperimetry: CERTAIN study report 4.

Acta ophthalmologica
2026

Clinical and imaging characteristics of central serous chorioretinopathy with subfoveal leak.

European journal of ophthalmology
2025

Resolved Central Serous Chorioretinopathy Mimicking Hydroxychloroquine Toxicity: A Case Series and Literature Review.

Diagnostics (Basel, Switzerland)
2025

Central Serous Chorioretinopathy and Diagnostic Challenges in Emergency Settings.

Advanced emergency nursing journal
2025

Three-Dimensional Choroidal Vessels Assessment in Fellow Eyes of Patients With Central Serous Chorioretinopathy.

Translational vision science &amp; technology
2025

Evaluation of Reflectivities of RPE, ELM, EZ, and Their Relationship With Subretinal Fluid Properties in Central Serous Chorioretinopathy.

Investigative ophthalmology &amp; visual science
2025

Classifying Subretinal Lucency: A Matter of Terminology and Resolution.

Retina (Philadelphia, Pa.)
2025

Predictive factors for the development of macular neovascularization in chronic central serous chorioretinopathy.

Scientific reports
2025

Morphological and Functional Outcomes in the Long-Term Natural Course of Peripapillary Pachychoroid Syndrome.

Ophthalmology and therapy
2025

Visual Acuity May Inadequately Reflect the Vision-related Quality of Life in Patients with Chronic Chorioretinopathy Centralis Serosa.

Klinische Monatsblatter fur Augenheilkunde
2025

Central serous chorioretinopathy imaging biomarkers as potential indicators of response to subthreshold nanosecond laser.

Indian journal of ophthalmology
2026

Controversies and conundrums in pachychoroid spectrum disorders: A structured diagnostic approach.

Survey of ophthalmology
2025

A Lightweight CNN for Multiclass Retinal Disease Screening with Explainable AI.

Journal of imaging
2025

A Novel Finding of Retinal Neovascularization Secondary to Chronic Central Serous Chorioretinopathy.

Cureus
2025

Taxane-associated retinopathy and radiation-induced optic neuropathy in a young female patient with metastatic breast cancer.

GMS ophthalmology cases
2025

Choriocapillaris perfusion assessed using optical coherence tomography angiography depends on eye color and projection artifact removal.

International ophthalmology
2025

Large Retinal Pigment Epithelium Tear in Central Serous Chorioretinopathy.

Ophthalmology. Retina
2025

Hyperreflective Foci in Blowout Pigmented Epithelium Detachment Secondary to Pachychoroid Mimicking Type 3 Macular Neovascularization.

Ophthalmic surgery, lasers &amp; imaging retina
2025

CPAP Use and Retinal Disease Risk in Obstructive Apnea: A Cohort Study.

Vision (Basel, Switzerland)
2025

Intraocular Pressure and Ocular Perfusion Pressure in Central Serous Chorioretinopathy.

American journal of ophthalmology
2025

[Long-term outcome after photodynamic therapy of persistent central serous chorioretinopathy].

Die Ophthalmologie
2025

Approach to optic disc swelling with macular subretinal fluid and choroidal folds: a narrative review.

Photodiagnosis and photodynamic therapy
2025

Remarkable response to dupilumab in refractory allergic bronchopulmonary mycosis with a giant mucus plug due to Aspergillus udagawae.

Respiratory investigation
2025

Anatomical and Functional Outcomes of Anti-VEGF Therapy in Pachychoroid Neovasculopathy.

Clinical ophthalmology (Auckland, N.Z.)
2025

Clinical Features and Optical Coherence Tomography Angiography in Neovascular Age-Related Macular Degeneration and Pachychoroid Neovasculopathy.

Journal of vitreoretinal diseases
2026

Central Serous Chorioretinopathy occurs in High Frequency in Myelin Oligodendrocyte Glycoprotein Antibody Disease, Seropositive and Seronegative Neuromyelitis Optica Spectrum Disorders compared to Multiple Sclerosis and Healthy Controls.

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
2025

Impact of the COVID-19 pandemic on the incidence and recurrence of central serous chorioretinopathy in Greece: a multicenter study.

International ophthalmology
2025

A case of macular damage following micropulse laser treatment for central serous chorioretinopathy.

The Journal of international medical research
2025

Global Incidence of Central Serous Chorioretinopathy: A Systematic Review, Meta-analysis, and Forecasting Study.

Ophthalmology and therapy
2025

Changes in choroidal vessel morphology associated with fluid leakage in central serous chorioretinopathy; a comparison of OCTA and ICGA.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
2025

Evaluation of Choroidal Vein Distribution Pattern and Choroidal Vessel Parameters in Patients With Central Serous Chorioretinopathy Using Widefield ICGA and Widefield OCTA.

American journal of ophthalmology
2026

Deep learning in central serous chorioretinopathy.

Survey of ophthalmology
2025

Two-year treatment outcome of photodynamic therapy combined with anti-vascular endothelial growth factor therapy for pachychoroid neovasculopathy.

Photodiagnosis and photodynamic therapy
2025

Association of central serous chorioretinopathy with single-nucleotide polymorphisms in Complement Factor H gene in a Chinese population.

International ophthalmology
2025

Central Serous Chorioretinopathy.

Advances in experimental medicine and biology
2025

Comprehensive analysis of pachyvessel morphology in central serous chorioretinopathy using multimodal imaging.

Scientific reports
2025

Characteristics of vortex vein in healthy eyes and fundus diseases imaged by ultra-widefield OCTA.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
2025

Evaluation of the therapeutic effects of smoking cessation on chronic central serous chorioretinopathy.

Scientific reports
2025

Acute bilateral retinal and choroidal detachment - A case report.

Retinal cases &amp; brief reports
2025

Research Progress in Artificial Intelligence for Central Serous Chorioretinopathy: A Systematic Review.

Ophthalmology and therapy
2025

Dark Adaptometry Kinetics Differentiates Age-Related Macular Degeneration from Central Serous Chorioretinopathy.

Ophthalmology science
2025

Comparison of microvasculature between neovascular, non-neovascular chronic central serous chorioretinopathy cases and asymptomatic fellow eyes using swept-source optical coherence tomography angiography.

International ophthalmology
2025

Photodynamic therapy-induced inflammation and adverse effects: An updated review.

Biomedical journal
2025

Central serous chorioretinopathy mimicking as choroidal hemangioma - A diagnostic challenge.

Oman journal of ophthalmology
2025

Treat and Extend Regimen of Aflibercept in the Treatment of Type 1 Choroidal Neovascularization Secondary to Chronic Central Serous Chorioretinopathy: Three-year Follow-Up.

Clinical ophthalmology (Auckland, N.Z.)
2025

Photodynamic therapy on chronic pathology during the post-COVID19 and worldwide shortage of verteporfin (Visudyne®) era.

Photodiagnosis and photodynamic therapy
2025

A Comparative Study on the Prevalence of Helicobacter pylori Infection in Patients with Central Serous Chorioretinopathy versus a Control Population.

Clinical ophthalmology (Auckland, N.Z.)
2025

Treatment of central serous chorioretinopathy: new options for an old disease.

Eye (London, England)
2026

Successful surgical repair of a ruptured medial rectus muscle accompanied with serous chorioretinopathy.

Strabismus
2025

Analysis of cytokine profiles in aqueous humor based on optical coherence tomography in pachychoroid spectrum diseases.

Scientific reports
2025

Influence of combined eplerenone, aflibercept and nepafenac therapy on central serous chorioretinopathy.

International journal of ophthalmology
2025

Interventions for central serous chorioretinopathy: a network meta-analysis.

The Cochrane database of systematic reviews
2025

Reduction in choroidal thickness associated with the progression of pachychoroid spectrum diseases.

Japanese journal of ophthalmology
2025

Eplerenone and Spironolactone for Chronic Central Serous Chorioretinopathy: A Systematic Review and Meta-Analysis.

American journal of ophthalmology
2025

Three-Dimensional Choroidal Contour Mapping in Healthy and Diseased Eyes.

Translational vision science &amp; technology
2025

The results of subthreshold 577 nm yellow laser application using pascal laser system in patients with chronic central serous chorioretinopathy.

Lasers in medical science
2025

Case Report: Kyrieleis plaques in an unusual Behcet's disease uveitis.

Frontiers in medicine
2025

Delayed Onset of Central Serous Chorioretinopathy following Corticosteroid Treatment for Giant Cell Arteritis: A Case Report.

Case reports in ophthalmology
2025

Posterior scleritis misdiagnosed as central serous chorioretinopathy: Case report.

Photodiagnosis and photodynamic therapy
2025

Central serous chorioretinopathy and autonomic dysfunction.

Indian journal of ophthalmology
2025

Evaluation of anterior scleral thickness in eyes with central serous chorioretinopathy.

Indian journal of ophthalmology
2025

Real-world use of a hydrophilic curcumin-based oral formulation in the management of macular oedema: a collection of clinical experiences.

Drugs in context
2025

Fractal analysis for OCT-A images of central serous chorioretinopathy.

Photodiagnosis and photodynamic therapy
Ver todos os 2.623 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Coriorretinopatia serosa central.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Coriorretinopatia serosa central

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ainda não achamos doenças com sintomas parecidos o suficiente.

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Combined Therapy Versus Fortified Anti-VEGF Monotherapy in Type C Polypoidal Choroidal Vasculopathy: Long-Term Outcomes and Exploratory Biomarker Insights.
    International journal of molecular sciences· 2026· PMID 41683651mais citado
  2. Correction: Effect of photodynamic therapy on choroid of the medial area from optic disc in patients with central serous chorioretinopathy.
    PloS one· 2026· PMID 41662234mais citado
  3. The CFH-CFHR5 Locus in Wet Age-Related Macular Degeneration, Polypoidal Choroidal Vasculopathy, and Central Serous Chorioretinopathy.
    Ophthalmology science· 2026· PMID 41626425mais citado
  4. Selective Retina Therapy With Fundus Image-Based Titration in Central Serous Chorioretinopathy: Prospective Outcomes and Predictive Factors.
    Translational vision science &amp; technology· 2026· PMID 41563733mais citado
  5. Neurosymbolic AI Framework for Explainable Retinal Disease Classification From OCT Images.
    Translational vision science &amp; technology· 2026· PMID 41533847mais citado
  6. Treatment of Central Serous Chorioretinopathy With Topical Difluprednate: A Literature Review.
    Cureus· 2026· PMID 41994738recente
  7. Migraine as a risk factor for retinal vascular events and maculopathies: a systematic review and meta-analysis of 47 million individuals.
    J Headache Pain· 2026· PMID 41987034recente
  8. Non-Neoplastic Uveitis Masquerade Syndromes: Insights from a Case Series.
    Ocul Immunol Inflamm· 2026· PMID 41973951recente
  9. Correlation of CS and OCTA biomarkers in CSCR.
    Rom J Ophthalmol· 2025· PMID 41971200recente
  10. Central Serous Chorioretinopathy Following Corticosteroid Injection for Thumb Carpometacarpal Osteoarthritis: A Case Report.
    J Orthop Case Rep· 2026· PMID 41970790recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:443079(Orphanet)
  2. MONDO:0018616(MONDO)
  3. GARD:200(GARD (NIH))
  4. Busca completa no PubMed(PubMed)
  5. Artigo Wikipedia(Wikipedia)
  6. Q1431217(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Coriorretinopatia serosa central
Compêndio · Raras BR

Coriorretinopatia serosa central

ORPHA:443079 · MONDO:0018616
CID-10
H35.7 · Separação das camadas da retina
CID-11
Ensaios
10 ativos
MedGen
UMLS
C0730328
EuropePMC
Wikidata
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades